In the course of selecting its holdings, BB BIOTECH relies on the well-established experience of its management board members and the fundamental analyses by the experienced Management Team of Bellevue Asset Management AG, with access to a network of physicians and specialists for the sectors in question. In doing so, a detailed financial model is created for each holding, which guarantees a compelling illustration of the potential for doubling asset values in a period of four years. This potential is based on innovative power, new products for serious illnesses and outstanding management.

Before making a positive investment decision, intensive contact is established with the management, since we are convinced that an outstanding performance can only be achieved with a strong management. After being incorporated into BB BIOTECH’s portfolio, intense personal contact with members of the management of the relevant holdings is maintained and extended.

This closely knit monitoring of the portfolio companies enables
BB BIOTECH to utilize all strategic options on a timely basis, including early disposal of an equity interest when the fundamental situation deteriorates significantly.